Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 12/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140045 | 0.95 | CDK4 (0.40) | CDK4CDK6CCND1CDK2HRH3 | |
| SCHEMBL4422276 | 0.92 | HRH3 (0.37) | CDK4CDK6HRH3 | |
| SCHEMBL4139732 | 0.88 | MCHR1 (0.43) | CDK4CDK6CDK2HRH3 | |
| SCHEMBL4130682 | 0.85 | MCHR1 (0.49) | CDK4CDK6HRH3 | |
| SCHEMBL4131366 | 0.85 | MAPT (0.43) | HRH3 | |
| SCHEMBL4136714 | 0.84 | L3MBTL3 (0.51) | CDK4HRH3 | |
| SCHEMBL4130945 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL4130776 | 0.84 | KDM4E (0.46) | CDK4CDK6CCND1CDK2HRH3 | |
| SCHEMBL4289427 | 0.83 | L3MBTL3 (0.50) | CDK4HRH3 | |
| SCHEMBL4938014 | 0.83 | HRH3 (0.42) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | CDK4 2945/4885CDK6 1532/4885CCND1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.